5 Biotech Stocks to Buy for 2015
These five biotech stocks may have what it takes to reward investors next year.
This Could Be the Next Big Pharma Buyout
Three Motley Fool analysts tell investors which three companies they think would be ripe for an acquisition.
Should Johnson & Johnson Buy Medivation Inc.?
Johnson & Johnson's top-selling prostate cancer treatment is facing a stiff challenger in Medivation's Xtandi, but an acquisition may not be in the cards.